Related Experiment Videos
Modulation of lung tumor development in mice with the soybean-derived Bowman-Birk protease inhibitor
1Toxic Substances Research and Teaching Program, University of California, Davis 95616.
Abstract:
Male strain A mice were treated with a single i.p. injection of 3-methylcholanthrene (MCA). Four months later, the number of lung tumors was counted. In mice treated three times a week, for 8 weeks, with crude soybean extract containing the Bowman-Birk protease inhibitor (BBI), the number of lung tumors was significantly lower than in control animals receiving carcinogen treatment only (40-70% of controls). On the other hand, treatment initiated 8 weeks after MCA only had no effect on tumor development. A reduction in the number of lung tumors was also found in animals treated i.p. or orally with purified BBI three times a week for 8 weeks following MCA administration. It is concluded that BBI is capable of partially blocking the development of lung tumors in mice.
Insights
Bowman-Birk protease inhibitor (BBI) from soybean extract can reduce lung tumor development in mice. Early BBI treatment after carcinogen exposure showed significant tumor reduction, but delayed treatment had no effect.
Area of Science:
- Chemoprevention
- Carcinogenesis
- Molecular Biology
Background:
- 3-methylcholanthrene (MCA) is a potent carcinogen that induces lung tumors in mice.
- Protease inhibitors, such as Bowman-Birk inhibitor (BBI), are being investigated for their chemopreventive potential.
Purpose of the Study:
- To evaluate the efficacy of Bowman-Birk protease inhibitor (BBI) in preventing 3-methylcholanthrene (MCA)-induced lung tumorigenesis in mice.
- To determine the effect of treatment timing on BBI's chemopreventive activity.
Main Methods:
- Male strain A mice were administered a single intraperitoneal injection of MCA.
- Mice received crude soybean extract or purified BBI (intraperitoneal or oral) three times weekly for 8 weeks, either concurrently with or after MCA administration.
- Lung tumor counts were performed four months post-MCA treatment.
Main Results:
- Concurrent treatment with crude soybean extract containing BBI significantly reduced lung tumor multiplicity (40-70% of controls).
- Treatment with purified BBI, administered concurrently via intraperitoneal or oral routes, also resulted in a reduction of lung tumors.
- Delayed BBI treatment, initiated 8 weeks after MCA administration, did not affect tumor development.
Conclusions:
- Bowman-Birk protease inhibitor (BBI) demonstrates partial blocking activity against lung tumor development induced by MCA.
- The timing of BBI administration is critical for its chemopreventive efficacy, with early intervention being key.